Caladrius

Caladrius Biosciences, Inc. (Caladrius, formerly NeoStem) is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.
Type
Public
HQ
Allendale, US
Founded
2006
Employees
221 (est)+22%
Caladrius was founded in 2006 and is headquartered in Allendale, US

Key People at Caladrius

Robin L. Smith

Robin L. Smith

CEO

Caladrius Locations

Allendale, US
Mountain View, US

Caladrius Metrics

Caladrius Summary

Market capitalization

$28.3 M

Closing share price

$4.83
Caladrius's latest market capitalization is $28.3 M.

Caladrius Market Value History

Caladrius Online Presence

Caladrius Company Life

You may also be interested in